Adjusting MTX dose improves psoriasis response

Share this article:
Adjusting MTX dose improves psoriasis response
Adjusting MTX dose improves psoriasis response

Methotrexate is an effective treatment for children with atopic dermatitis, psoriasis or psoriasis-eczema overlap. However, some patients may require dose modification to achieve complete response, according to results of a recently published study.

Syed I. Rahman, BA, of Saint Louis University School of Medicine, and colleagues published in the Journal of the American Academy of Dermatology a retrospective review of 46 patients aged 2 to 7 years (median 8 years) who were treated with methotrexate (MTX) for inflammatory skin diseases. The mean duration of treatment was 363 days, and 60% of children responded within three months.

Of those 46 children, 38 children achieved good to excellent response. Twenty-seven children achieved a good response within 12 weeks, and the remaining children achieved a desirable response after dose-adjustment, according to the researchers.

Children with psoriasis/overlap had the highest responses (94%) noted as good to excellent compared with atopic dermatitis (77%). Mean maximum polyglutamate levels were 31.5 nmol/L for children who responded versus 18.1 nmol/L for patients who did not respond (P= 0.035).

Following dose modification, children considered late responders achieved a significantly higher mean maximum methotrexate polyglutamate assay (41.9 nmol/L) compared with those who did not respond (P=0.002). This difference was also significant for the subset with atopic dermatitis, Rahman and colleagues wrote, but not for patients with psoriasis-eczema overlap.

“MTX is an effective treatment for the majority of children with inflammatory skin diseases, but a subset requires dose modification to achieve good to excellent response. Methotrexate polyglutamate assay levels reflect response to treatment, but are most useful to support dose modification among children who fail to respond within 12 weeks,” the researchers concluded.

References

  1. Rahman SI. J Am Acad Dermatol. 2013;doi: 10.1016/j.jaad.2013.10.001.
Share this article:
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Psoriasis Information Center

Sign Up for Free e-newsletters

More in Psoriasis Information Center

Less stress equals better-looking skin

Less stress equals better-looking skin

Research into blocking specific steps in certain pathways between the nervous system and the skin could lead to improved treatment of some skin disorders.

Sacroiliitis could be surrogate marker for CVD in psoriasis patients

Sacroiliitis could be surrogate marker for CVD in ...

Sacroiliitis predicted vascular inflammation beyond psoriatic arthritis and cardiovascular risk factors.

Cancer rates higher among patients with psoriasis

Cancer rates higher among patients with psoriasis

Researchers analyzed cancer rates for different psoriasis treatments, but did not find a significantly greater risk associated with any particular therapy.